Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Reverberi

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
Advances in Radiation Oncology|October 27, 2025
Are There High-Risk Prognostic Factors for Isolated Locoregional Recurrence in Patients With Early-Stage Breast Cancer Treated With Mastectomy Without Adjuvant Radiation Therapy?Giuseppe Facondo, Chiara Reverberi, Agnese Prisco, et al.
Journal for Immunotherapy of Cancer|April 13, 2019
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicityGiuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, et al.
Anticancer Research|October 1, 2021
Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case StudyDimitri Anzellini, Vitaliana DE Sanctis, Maurizio Valeriani, et al.
Radiation Oncology Journal|October 13, 2018
Single nucleotide polymorphism of <italic>GSTP1</italic> and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapyLuca Nicosia, Giovanna Gentile, Chiara Reverberi, et al.
Journal of Cancer Research and Clinical Oncology|January 23, 2021
Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)Chiara Reverberi, Stefania Volpe, Damiano Balestrini, et al.
International Journal of Radiation Oncology, Biology, Physics|February 24, 2025
Preoperative Single Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer Patients With GammaPod Technology: Pathologic Findings and Ki-67 EvaluationChiara Reverberi, Giuseppe Facondo, Agnese Prisco, et al.
Journal of Clinical Medicine|December 11, 2022
Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) TechniquesFabrizio Tonetto, Alessandro Magli, Eugenia Moretti, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 14, 2025
Dose-response modelling of stereotactic radiosurgery for brain metastases: Preliminary prospective data from the SAFER study (IRAS 276567)James de Boisanger, Amina Tran, Philip Benjamin, et al.
Anticancer Research|March 2, 2018
Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term OutcomesMaurizio Valeriani, Pierluigi Bonfili, Chiara Reverberi, et al.
International Journal of Radiation Oncology, Biology, Physics|December 1, 2020
Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical TrialMarco Trovo, Alberto Relevant, Jerry Polesel, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Advances in Radiation Oncology|October 27, 2025
Are There High-Risk Prognostic Factors for Isolated Locoregional Recurrence in Patients With Early-Stage Breast Cancer Treated With Mastectomy Without Adjuvant Radiation Therapy?Giuseppe Facondo, Chiara Reverberi, Agnese Prisco, et al.
Journal for Immunotherapy of Cancer|April 13, 2019
Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicityGiuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, et al.
Anticancer Research|October 1, 2021
Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case StudyDimitri Anzellini, Vitaliana DE Sanctis, Maurizio Valeriani, et al.
Radiation Oncology Journal|October 13, 2018
Single nucleotide polymorphism of <italic>GSTP1</italic> and pathological complete response in locally advanced rectal cancer patients treated with neoadjuvant concomitant radiochemotherapyLuca Nicosia, Giovanna Gentile, Chiara Reverberi, et al.
Journal of Cancer Research and Clinical Oncology|January 23, 2021
Post-operative management of brain metastases: GRADE-based clinical practice recommendations on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO)Chiara Reverberi, Stefania Volpe, Damiano Balestrini, et al.
International Journal of Radiation Oncology, Biology, Physics|February 24, 2025
Preoperative Single Fraction Stereotactic Partial Breast Irradiation for Early-Stage Breast Cancer Patients With GammaPod Technology: Pathologic Findings and Ki-67 EvaluationChiara Reverberi, Giuseppe Facondo, Agnese Prisco, et al.
Journal of Clinical Medicine|December 11, 2022
Prostate Cancer Treatment-Related Toxicity: Comparison between 3D-Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) TechniquesFabrizio Tonetto, Alessandro Magli, Eugenia Moretti, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 14, 2025
Dose-response modelling of stereotactic radiosurgery for brain metastases: Preliminary prospective data from the SAFER study (IRAS 276567)James de Boisanger, Amina Tran, Philip Benjamin, et al.
Anticancer Research|March 2, 2018
Moderate Hypofractionation in Patients with Low-risk Prostate Cancer: Long-term OutcomesMaurizio Valeriani, Pierluigi Bonfili, Chiara Reverberi, et al.
International Journal of Radiation Oncology, Biology, Physics|December 1, 2020
Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical TrialMarco Trovo, Alberto Relevant, Jerry Polesel, et al.
Pageof 3